tiprankstipranks
Elite Pharmaceuticals files ANDA with FDA to market dopamine agonist
The Fly

Elite Pharmaceuticals files ANDA with FDA to market dopamine agonist

Elite Pharmaceuticals announced that it filed an Abbreviated New Drug Application with the US Food and Drug Administration for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists. For the twelve months ending August 31, 2022, the dopamine agonist had total US sales of approximately $12 million, according to IQVIA data.

Published first on TheFly

See the top stocks recommended by analysts >>

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles